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Summary
Motivated by a previously published study of HIV treatment, we simulated data subject to time-
varying confounding affected by prior treatment to examine some finite-sample properties of
marginal structural Cox proportional hazards models. We compared (a) unadjusted, (b) regression-
adjusted, (c) unstabilized and (d) stabilized marginal structural (inverse probability-of-treatment
[IPT] weighted) model estimators of effect in terms of bias, standard error, root mean squared
error (MSE) and 95% confidence limit coverage over a range of research scenarios, including
relatively small sample sizes and ten study assessments. In the base-case scenario resembling the
motivating example, where the true hazard ratio was 0.5, both IPT-weighted analyses were
unbiased while crude and adjusted analyses showed substantial bias towards and across the null.
Stabilized IPT-weighted analyses remained unbiased across a range of scenarios, including
relatively small sample size; however, the standard error was generally smaller in crude and
adjusted models. In many cases, unstabilized weighted analysis showed a substantial increase in
standard error compared to other approaches. Root MSE was smallest in the IPT-weighted
analyses for the base-case scenario. In situations where time-varying confounding affected by
prior treatment was absent, IPT-weighted analyses were less precise and therefore had greater root
MSE compared with adjusted analyses. The 95% confidence limit coverage was close to nominal
for all stabilized IPT-weighted but poor in crude, adjusted, and unstabilized IPT-weighted
analysis. Under realistic scenarios, marginal structural Cox proportional hazards models
performed according to expectations based on large-sample theory and provided accurate
estimates of the hazard ratio.
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1. Introduction
Marginal structural Cox proportional hazards models were introduced in 1998 [1] and have
rapidly disseminated into biomedical research over the last decade [2–19]. Marginal
structural Cox proportional hazards models were developed to estimate causal effects in the
presence of time-varying confounding affected by prior treatment. In such settings standard
statistical methods, such as Cox proportional hazards models with time-varying covariates
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[20] fail to consistently estimate the total effect of a time-varying treatment (or exposure)
even in the absence of unmeasured confounding and unmeasured informative censoring [3].
The conditions necessary for a marginal structural Cox proportional hazards model to
provide unbiased estimates of effects include: consistency, positivity, no unmeasured
confounders, no unmeasured informative censoring, and correct model specification. Here
we define consistency and positivity because these are less well-known than the remaining
conditions. Consistency, not to be confused with statistical consistency (i.e., the property of
convergence in probability to the true value as the sample size tends to infinity), is the
assumption that an individual’s potential outcome under her observed treatment is precisely
her observed outcome: formally,  if Xi = x for participant i, where X is treatment, Y is
the outcome and Yx is the potential outcome under treatment x[21]. Positivity, also known
as the experimental treatment assumption [22], requires that there are both treated and
untreated individuals at every combination of the values of the confounders in the observed
data: formally, for a discrete-valued treatment X and arbitrary confounder vector Z, if f(Zi)
≠ 0 then  for all , where f(.) is the probability density function [23].
Given the above stated conditions, the large-sample properties of inverse probability-of-
treatment (IPT) weighted estimators of a marginal structural Cox proportional hazards
model have been described [1, 24]. In brief, the IPT-weighted estimator of a marginal
structural Cox proportional hazards model provides a regular, asymptotically linear
estimator of a contrast in potential outcomes [24]. Given data Di, sample size n, and the
influence function ψ(Di), a measurable random function with expectation 0, an estimator
using sample size n, , of a parameter β is regular and asymptotically linear if
 and if  has a limiting distribution that does
not depend on the local data generating process [25]. Again, under the above stated
conditions, a hazard ratio from a marginal structural Cox proportional hazards model is
asymptotically unbiased provided that the model for the probability of treatment (used to
estimate the IPT weights) converges to the true probability of treatment at a rate of at least
n1/4.
Granting the (largely un-testable) conditions listed above and despite favorable large-sample
properties, if marginal structural Cox proportional hazards models have poor finite sample
properties then their general use will be limited. For instance, if IPT-weighted estimators are
notably biased under realistic sample and effect sizes, then this finite-sample bias may well
preclude their recommendation as a tool in applied research. To our knowledge, there exists
no study of the finite-sample properties of the marginal structural Cox proportional hazards
model under realistic research settings. Here we present results from such a study. In section
2, we review the marginal structural Cox proportional hazards model. In section 3, we
describe a motivating example from HIV/AIDS. In section 4, we describe the simulation
design. In section 5, we summarize the simulation results. We close in section 6 with a
discussion.
2. Marginal structural Cox proportional hazards model
Let the data consist of n copies of the independent and identically distributed set {Z(t), X(t),
T}i, where i = 1 to n, Z(t) is a vector of time-varying covariates, X(t) is a time-varying
treatment of interest, and Ti is the minimum of Ti* and Ci, where Ti* is the time from study
entry to the event of interest and Ci is the time from study entry to right-censoring.
Uppercase letters represent random variables and lowercase letters represent possible
realizations. We assume no unmeasured informative censoring, or
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 The history of a time-varying variable is denoted
using overbars, so that  is the observed treatment history
for participant i, and  is a possible treatment history.
Examples of possible histories  include always treated {1,1,…,1} and never treated {0,0,
…,0}.
A marginal structural Cox proportional hazards model is , where
 is the hazard at time t had all participants (possibly contrary to fact) been assigned
treatment history , λ0(t) is the hazard at time t had all participants been assigned treatment
history . We assume the function of treatment history  is the cumulative average
treatment  but other specifications are possible. In the above model exp
(δW) is a hazard ratio for a unit increase in  and is a contrast of potential outcomes. Note
that here  ranges from 0 to 1, so that a unit difference in the cumulative average
treatment  corresponds to always versus never-treated, the contrast of interest in our
setting.
The hazard ratio exp(δW) may be estimated by fitting an unadjusted Cox proportional
hazards model on the observed data weighted by a stabilized time-varying IPT weight,
which is estimated from the observed data and defined as
where f [·|·] is the conditional density function evaluated at the observed covariate values for
a given participant. The unstabilized weights simply replace the numerator of Wi(t) with 1.
When X(t) has a Bernoulli distribution, the denominator of the weight is equivalent to a
time-varying generalization of the propensity score among the treated [26] and the
complement of this generalization among the untreated. The denominator of this weight
corresponds to each patient’s probability of their entire treatment history up to each time
point; these weights create a pseudopopulation in which treatment at each time is unrelated
to the time-varying confounders. The numerator of the weight is a stabilizing factor which
reduces the variance of the weighted estimator and which is a function of treatment that does
not depend on time-varying confounders.
3. Motivating empirical example: Antiretroviral therapy for HIV and
incidence of AIDS or death
Here we describe a motivating example from HIV/AIDS [6]. In this example, estimates from
a marginal structural Cox proportional hazards model fit to observational data cohered well
with substantive knowledge and existing randomized evidence. Moreover, these estimates
differed from estimates from standard Cox proportional hazards models with time-varying
covariates fit to the same data [6, 8].
The study population comprised participants from two ongoing US multicenter prospective
studies of HIV namely, the Multicenter AIDS Cohort Study and the Women’s Interagency
HIV Study. The treatment was use of highly active antiretroviral therapy (henceforth
therapy), and the outcome was time from study entry to the primary clinical AIDS defining
illness or death from any cause. Participants (n=1,498) entered study for this investigation in
1995. Over a median (quartiles) follow-up of 5.4 (3.0, 5.9) years, approximately 47% of
person-time was exposed to therapy and 382 participants had an incident diagnosis of
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clinical AIDS or died (cumulative incidence 28%). The results of crude, adjusted, and
marginal structural (IPT-weighted) Cox proportional hazards model analyses were as
follows: 0.98 (95% confidence limits [CL]: 0.76, 1.26), 0.81 (95% CL: 0.61, 1.07), and 0.54
(95% CL: 0.38, 0.78), respectively [6]. Crude (panel A) and IPT-weighted (panel B)
cumulative incidence curves are shown in Figure 1[27, 28]. Results were thus close to the
null hazard ratio in both crude and adjusted analyses, but substantially different in the IPT-
weighted analysis. Moreover, the estimate from the IPT-weighted analysis was closer than
the crude or adjusted results to findings from randomized studies of therapy for the
prevention of AIDS or death. For example, pooling results from two large randomized
studies [29, 30] yields a summary hazard ratio for AIDS of 0.52 (95% CL: 0.43, 0.64)
comparing treatment with therapy to standard care.
4. Simulation
Simulation Design
A simulated data record comprises values for Z(k), X(k),  and T, for k = 0 to 9
assessments. We first generated the potential survival time under no treatment, T0, from the
Weibull distribution with hazard , where the Weibull shape parameter σ = 0.75 and
rate parameter λ = exp(0). Next, we generated the potential survival times under the 10
possible non-zero treatment levels for cumulative average treatment with 10 assessments as
 where φ= 0.924 for the base-case scenario. Therefore the hazard ratio
exp(δW) for always treated  compared to never treated  was
. Due to a dichotomous treatment at ten time points, there are 210
possible treatment histories; however, we concern ourselves with the cumulative average
treatment effect here. We note that these exposure patterns are similar but more general than
the typical “once-treated, always-treated” intent-to-treat assumptions in applied work in
HIV[6]; in most examples, the intent-to-treat assumption is only approximately true.
The measured time-varying confounder Z(k) is determined in part by T0 and by X(k − 1) by
the models  for k = 1 to 9, and
 for k = 0, where expit(.) = exp(.) / [1+exp(.)], β0 was chosen to
maintain a marginal probability of 0.5, ß1 was set to log(2) in the base-case, and β2 was set
to log(0.5) for all scenarios. The time-varying treatment X(k) is determined in part by Z(k)
by the model , for k = 0 to 9, where γ0 was chosen to
maintain a marginal probability of 0.5 in the base-case, and γ1 was set to log(2).
The observed event time T was assigned as the one of 11 potential event times that
coincided with the observed treatment history, namely , where
. Observed event times were administratively censored to yield 20%
events. Akin to prior illustrative examples [3], for simplicity we assume events always occur
temporally posterior to all treatment assessments. Such an assumption is not required
generally for marginal structural models [1, 31].
Figure 2 is a causal diagram [32] representing the simulated data. In Figure 2, arrows
represent direct causal effects, or contrasts in potential outcomes [33, 34]. In Figure 2, Z(k
+1) is time-varying confounder affected by prior treatment; Z(k+1) is related to outcome
through T0. Therefore, failing to adjust for Z(k+1) will bias the estimate of treatment effect
on T through the open bias path . Adjusting for Z(k+1) blocks
this aforementioned bias path, but opens a collider-stratification bias path
 and again results in a biased estimate of the treatment effect on T.
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Simulation base-case values were chosen so that weighted and adjusted estimates coincided
with results from previously published examples [6, 35, 36]. We explored 40 scenarios
defined by varying the sample size n as 1500 for the base-case and 200; the true effect of
treatment as a hazard ratio of 0.5 for the base-case and 1.0; a treatment prevalence of 0.5 for
the base-case and 0.2; and the magnitude of treatment X(k) on confounder Z(k+1) as β1 =
log(2) for the base-case and {0.5, 0.75, 1, 1.5}. We conducted 5000 simulations for each
scenario. The simulation standard error for 5000 simulations is approximately 1/3% for
estimates of the 95% CL coverage [37].
Simulation Analysis
We conducted four analyses estimating the hazard ratio for the effect of treatment on
outcome. First, we estimated the unadjusted association obtained from a standard Cox
proportional hazards model with the sole covariate  as , where
h0(t) is an unspecified hazard at time t for the group with  and δC is the estimated
crude log hazard ratio for a unit difference in . This analysis estimates the unadjusted
hazard ratio for a unit change in the cumulative average treatment.
Second, we estimated the adjusted association obtained from a standard Cox proportional
hazards model with the two covariates,  (defined as above) and the vector of covariates
Z as , where h0(t) is an unspecified hazard at time t for the
group with , δA is the estimated log hazard ratio for a unit difference in 
holding the vector of covariate indicators Z constant at any level. This analysis estimated the
Z-adjusted hazard ratio for a unit change in the same cumulative average treatment. We
conducted a sensitivity analysis using cumulative average Z instead of a vector of indicators
for each Z(k); results were similar as in main analysis.
Third and fourth we estimated the association obtained from a marginal structural Cox
proportional hazards model estimated using IPT weights as , where
h0 (t) is an unspecified hazard at time t for the group with , δW is the estimated log
hazard ratio for a unit difference in .
For each of these four analyses (i.e., crude, adjusted, unstabilized weighted, stabilized
weighted) we estimated simulated bias, simulated standard error, simulated 95% CL
coverage, and simulated root mean squared error (MSE). Bias was computed as the average
difference between an estimator and the true log hazard ratio. The average standard error
was based on the robust variance. The Monte Carlo standard error was defined as the
simulated standard deviation of an estimator. Confidence limit coverage was computed as
the proportion of times the CL contained the true hazard ratio. Root mean squared error was
calculated by taking the square root of the sum of the bias and the square of the Monte Carlo
standard error. Convergence was obtained in all simulations.
Additional simulations were performed using a different causal structure with only two time
points but a wider range of simulation scenarios (432 scenarios, including use of a
lognormal failure time distribution). These alternate simulations provided the same
qualitative conclusions as the main results, and so are not described further; details are
available from the authors.
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Simulations for the base-case reflected key characteristics of the motivating example [6].
For example, the IPT-weighted hazard ratio was 0.54 in the motivating example [6], and
0.51 in the simulated data. Likewise, the adjusted hazard ratio in the motivating example
was 0.81, and 0.85 in the simulated data. Tables 1 through 4 show estimated bias, standard
error, root mean squared error, and 95% CL coverage, respectively, for the 40 scenarios
explored.
Table 1 shows bias; in the base-case scenario (first row), bias was notably large and toward
the null in both the unadjusted and adjusted analyses, severely attenuating and reversing the
true log-hazard ratio, respectively. In contrast, the stabilized IPT-weighted analysis was
essentially unbiased. These findings were robust to changes in the sample size, true hazard
ratio, and the effect of treatment on the time-varying confounder. However, analysis with
unstabilized weights was notably biased with the fairly rare treatment (i.e. 20%). This bias
may reflect non-positivity due to the relatively small probability of treatment [23]. Crude
and adjusted analyses were generally biased. However, when β = 0 (i.e., there was no effect
of treatment on the time-varying confounder), confounding was unaffected by prior
treatment and thus a simple adjusted analysis was unbiased. For example, when taking the
base-case scenario but with β = 0, bias for the adjusted analysis was −0.055, and for the
weighted analyses was 0.010 (Table 1, row 5).
Table 2 shows estimated Monte Carlo standard error for all scenarios and analyses. In the
base-case scenario (first row) and in general, the standard error was smallest for crude
analyses, higher in the adjusted analyses, higher still in the stabilized weighted analyses, but
all were of the same magnitude. However, the unstabilized weighted standard errors were
notably larger, as expected. The effect of stabilization on reduction in standard error was
dramatic when treatment was rare (i.e., 20%), and modest when treatment was common (i.e.,
50%). When β = 0 and thus an adjusted analysis was unbiased (Table 1), the pattern and
magnitude of standard errors remained essentially the same.
Table 3 shows root MSE. Here, both weighted analyses (unstabilized root MSE = 0.583,
stabilized root MSE = 0.582) were clearly superior to either crude or adjusted analyses in the
main scenario (crude root MSE = 1.293, adjusted root MSE = 0.702). In general, the
adjusted and stabilized weighted analyses were superior to the crude analyses. However,
comparing adjusted to weighted analyses, there were few clear patterns of results across
scenarios. It is of note that when weights are unnecessary (i.e. β = 0), the adjusted analysis
has a superior root MSE to either IPT weighted analysis.
Last, Table 4 shows simulated 95% CL coverage from all scenarios. In the base-case
scenario and all other scenarios, unstabilized and stabilized weighted analyses had
essentially nominal coverage with a range from 93% to 96%. Crude and adjusted analyses
often had less than nominal coverage, with ranges of 7% to 84% for the crude and 60% to
95% for the adjusted.
One additional simulation was performed to examine the convergence of the marginal
structural model as a function of sample size. With other parameters held at base-case
values, we generated 5000 samples varying sample size n in {200, 400, 800, 1500, 2500,
5000}, and performed a linear regression of the estimated Monte Carlo standard error on nk,
where k varied between −2 and 1. We found the k that minimized the residual error to be
−0.524. Therefore, we estimated that the standard error approached zero at a rate of
approximately n−1/2, in line with the theoretical expectation.
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This study describes properties of marginal structural Cox proportional hazards models in
the presence and absence of time-varying confounding affected by prior treatment. We
found that IPT-weighted marginal structural models performed as well as or better than
unadjusted or adjusted Cox proportional hazards regression models in terms of bias and 95%
CL coverage across a wide range of scenarios motivated by an empirical example. As
expected, we also found that unadjusted and adjusted Cox models often perform better than
weighted models in terms of standard error.
This divergence in performance between metrics of bias and standard error leads to
predictably mixed results when considering root MSE: the advantage of a weighted model
depends on whether the increase in variance associated with weighting is outweighed by the
reduction in bias that the weighted model provides. For instance, in the fourth scenario the
adjusted analysis was biased yet precise yielding the same root MSE of 0.591 as the
analogous stabilized weighted analysis, which was unbiased yet less precise. However, this
adjusted estimate, which was both precise and biased, had relatively poor CL coverage
(85%) compared to the weighted analysis (95%). Of course, when a time-varying
confounder is not affected by prior treatment (i.e., β = 0), the adjusted model is unbiased and
thus has a clear advantage in both standard error and root MSE over marginal structural
models.
Previously, it was unknown whether discrepancies in crude, adjusted, and weighted results
in the original analysis [6] could be attributed to poor finite-sample performance of marginal
structural models. These simulation results suggest a better explanation for observed
discrepancies is a failure of the crude and adjusted analyses to produce unbiased estimates of
the effect, and the comparison of root MSE in the base-case scenario further suggests that
the increased variance associated with weighting versus adjusting was not too high a price to
pay in the original analysis. On a related note, while adjusted results are not generally
expected to precisely coincide with marginal results in non-collapsible effect estimates (such
as the hazard ratio and rate ratio [38]), non-collapsibility does not play a role if the null
hypothesis is true. Because contrasts in performance of adjusted and marginal models was
similar in both null and non-null scenarios, the differences seen in non-null scenarios are
unlikely to be explained by non-collapsibility.
This work has limitations. First, we only explored a limited region of the possible joint
parameter space. We defined 40 scenarios by combinations of values of n, the marginal
probability of treatment, the true hazard ratio, and the association between the treatment and
time-varying confounder. However, as noted above, we simulated an additional 432
scenarios in fewer time points; those results support the findings presented. Second, we
included only a single, dichotomous time-varying confounder; real world data and examples
[6] often include higher dimension covariate vectors. Thus, despite the fact that our
simulation was able to approximate results from an empirical example, this work may not
generalize to all real world situations of time-varying confounding affected by prior
treatment. Future work might extend these results by expanding on the dimension of
confounders and allowing the outcome to occur at any point during follow up: methods to
simulate such data are under development [39]. We assumed that models, including the
model for weights, were correctly specified.
Last, in applied settings, the existence of poorly or unmeasured confounders, informative
censoring, and model mis-specification may all sabotage inferences from observational data.
Nonetheless, without adequate finite-sample behavior when these assumptions do hold, the
use of marginal structural models could not be recommended. That finite-sample behavior
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appears to be good: marginal structural Cox models fit with stabilized inverse probability of
weights appear to give unbiased results with approximately nominal coverage down to
sample size of 200 and marginal prevalence of exposure of 20% (e.g., about 40 exposed
individuals), making them a potentially appropriate approach to even small data sets. Of
course, the need to control for additional confounders may hamper the use of these methods
in such small data sets.
We note that in this simulation, outcomes could only occur after the 10 time points (e.g., a
subject could not die at time t=4). This situation is analogous to numerous real world
scenarios; e.g., intrapartum exposures (say, to iron supplementation) and outcomes
measured at birth [40] or in the infant thereafter; or early life exposures such as education
before age 30 or parity and later-life outcomes such as development of dementia. Alternate
ways of simulating data appropriate for marginal structural models may have more
flexibility in this regard: for example, an alternative approach was published recently by
Young et al. that addresses this issue [41]. Another possible approach is to reverse the
algorithm for the parametric g-formula [42]: assume parametric distributions for
interrelations among exposure, covariates, and outcome; simulate data; then estimate using
the parametric g-formula to estimate parameters of a marginal structural model. While the
parametric g-formula requires substantial assumptions, these assumptions can be met in a
simulation context, and thus allows the unbiased estimation of the marginal structural model
using a method independent of inverse probability weights. Both these methods may be
explored in further work.
Those caveats notwithstanding, the present results provide, to our knowledge, the first
simulation study lending support to the use of marginal structural Cox proportional hazards
models in a setting representative of real-world data. Key strengths of this study include a
large number of study assessments, a relatively large number of scenarios explored based on
a motivating empirical example, small Monte Carlo simulation error, and coherence with
theoretical expectations. In conclusion, in the presence of time-varying confounding affected
by prior treatment, standard Cox proportional hazard models provide biased effect estimates,
while IPT-weighted estimation of marginal structural Cox proportional hazards models
provides approximately unbiased and relatively precise effect estimates.
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Effect of highly active antiretroviral therapy (compared to no therapy) on time to AIDS or
death under (A) crude and (B) weighted cumulative incidence curves.
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Causal diagram: T0 represents the unmeasured event time under no treatment, X(k)
represents the time-varying treatment at assessment k, Z(k) represents a time-varying
confounder at assessment k affected by prior time-varying treatment, and T represents the
observed event time.
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